331 related articles for article (PubMed ID: 19365555)
1. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
2. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
3. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
4. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
5. Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).
Abraham RS; Geyer SM; Ramírez-Alvarado M; Price-Troska TL; Gertz MA; Fonseca R
J Clin Immunol; 2004 Jul; 24(4):340-53. PubMed ID: 15163890
[TBL] [Abstract][Full Text] [Related]
6. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
7. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
9. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
10. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
[TBL] [Abstract][Full Text] [Related]
11. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
12. Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy.
Gu M; Wilton R; Stevens FJ
Contrib Nephrol; 2007; 153():156-81. PubMed ID: 17075229
[TBL] [Abstract][Full Text] [Related]
13. Structural alterations within native amyloidogenic immunoglobulin light chains.
Randles EG; Thompson JR; Martin DJ; Ramirez-Alvarado M
J Mol Biol; 2009 May; 389(1):199-210. PubMed ID: 19361523
[TBL] [Abstract][Full Text] [Related]
14. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
15. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
16. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
[TBL] [Abstract][Full Text] [Related]
17. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
[TBL] [Abstract][Full Text] [Related]
18. Towards understanding the structure-function relationship of human amyloid disease.
Dealwis C; Wall J
Curr Drug Targets; 2004 Feb; 5(2):159-71. PubMed ID: 15011949
[TBL] [Abstract][Full Text] [Related]
19. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis.
Enqvist S; Sletten K; Stevens FJ; Hellman U; Westermark P
PLoS One; 2007 Oct; 2(10):e981. PubMed ID: 17912358
[TBL] [Abstract][Full Text] [Related]
20. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
